Amgen beats Q1 earnings, revenue estimates. Stock flat.


00:00 Speaker A

Biotech company Amgen out with first quarter results. Shares are rising just a bit. Yahoo! Finance’s Angelica Conlan is joining us now with those numbers. Hey, Ange.

00:09 Angelica Conlan

Hey, that’s right. And they are going to be probably, uh, trading a little bit on the flatter side because they met, uh, uh, expectations on revenue. 8.1 billion is what they came in with for the quarter and then beat on earnings per share, 4.90 instead of 4.25 expected from the street. Amgen, the story there is quite a diversified portfolio. So looking good on a number of fronts and a number of drugs there, but the story that we’ve all been waiting for, of course, is for them to enter the obesity market and whether or not Meritide is going to carry them into, you know, really a hotter space, uh, than they currently are in. We know the company’s been busy with a few deals in the last few years and looks like that’s all coming to root right now with the, uh, with the good earnings that they’ve had for the, for the quarter.

00:55 Speaker A

Thanks so much, Ange. Appreciate it.


Leave a Reply

Your email address will not be published. Required fields are marked *